Lungs News and Research

RSS

FDA's proposed label changes for LABA asthma medications: GSK reviews

GlaxoSmithKline is reviewing label changes proposed today by the US Food and Drug Administration (FDA) for asthma medications containing long-acting beta-agonists (LABAs), such as GSK's Advair (salmeterol / fluticasone propionate). GSK and makers of the other affected medicines containing LABAs have 30 days to agree with the proposed changes or state why they are not warranted.

19 Feb 2010

Asthma: LABAs should not be used alone

The U.S. Food and Drug Administration today announced that drugs in the class of long-acting beta agonists (LABAs) should never be used alone in the treatment of asthma in children or adults. Manufacturers will be required to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medications.

19 Feb 2010

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics Inc. reported today its results for the quarter and year ended December 31, 2009. The company reported net income attributable to common stockholders of $1.7 million, or $0.02 per share, basic and diluted, for the fourth quarter of 2009, compared with net income attributable to common stockholders in the fourth quarter of 2008 of $3.9 million, or $0.06 per share, basic and diluted.

18 Feb 2010

Travellers are likely to become increasingly exposed to canecutter's disease: Study

A team led by PhD researcher Dr Colleen Lau from the School of Population Health http://www.sph.uq.edu.au/ , has discovered the disease, known medically as leptospirosis, was traditionally a concern for males working in the agricultural and livestock industries, as it is contracted from contact with the urine of host animals.

18 Feb 2010

Norwegian government task force suggests formation of single company to commercialise biomaterial assets

Having studied the ethical, judicial and political arguments, the Norwegian government task force has suggested that a single nationwide company should be formed to commercialise biomaterials assets from the country’s various sources. The task force has also recommended HUNT Biosciences be a model for the national company.

18 Feb 2010

State-of-the-art review of stereological methods for lung morphometry

The ATS and the European Respiratory Society have issued official standards for the quantitative assessment of lung structure.

18 Feb 2010

Pfizer Canada accepts entries for seventh round of competition for Pfizer CVRAP

Pfizer Canada is currently accepting entries for its seventh round of competition for the Pfizer Cardiovascular Research Awards program (CVRAP). The program, first launched in October 2005, was developed to fund and support independent cardiovascular research in Canada.

18 Feb 2010

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

18 Feb 2010

Sorin Group's newest generation C5 HLM system receives FDA clearance

Sorin Group, a global company and a leader in the treatment of cardiovascular diseases, announced today the U.S. Food and Drug Administration (FDA) clearance of its newest generation C5 Heart-Lung Machine (HLM).

18 Feb 2010

Viral infection can suppress immune response to secondary bacterial infection

A new study reveals how infection with the influenza virus impacts the way that the immune system responds to subsequent infections. The research, published by Cell Press in the February 18th issue of the journal Cell Host and Microbe, provides a new understanding of the physiological and pathological consequences of the flu.

18 Feb 2010

OTRC: Secondhand smoke exposure is a serious health hazard

New research by the Oklahoma Tobacco Research Center (OTRC) shows that concentrations of secondhand tobacco smoke inhaled in smoking rooms of restaurants and bars are exceptionally high and hazardous to health.

17 Feb 2010

Role of surgery and subsequent need for RT in treatment of stage I SCLC

Research published in February's edition of the Journal of Thoracic Oncology investigates the utilization of surgery and the subsequent need for radiotherapy (RT) when treating stage I small cell lung cancer (SCLC). Traditionally, SCLC treatment regimes include chemotherapy and radiotherapy for limited stage disease; however, the study concludes that in selected patients with early stage disease a lobectomy (removal of lung) had an excellent overall survival without additional treatment.

17 Feb 2010

Low RVEF increases risk of death in patients with systolic heart failure

New research from the University of Alabama at Birmingham (UAB) suggests that the ability of right side of the heart to pump blood may be an indication of the risk of death to heart-failure patients whose condition is caused by low function by the left side of their heart.

17 Feb 2010

Study: Earlier detection of lung cancer can reduce number of late stage lung cancer deaths

The first ever actuarial analysis of lung cancer mortality, published today in Population Health Management Journal, provides strong evidence that earlier detection could reduce the number of late stage lung cancer deaths by over 70,000 people each year in the US.

17 Feb 2010

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Research published in the February edition of the Journal of Thoracic Oncology sought to assess the overall efficacy of split-course palliative chest radiotherapy (RT) for symptom relief in patients with advanced non-small cell lung cancer. Additionally, researchers investigated the impact the regimen's two-week break has on survival outcomes.

17 Feb 2010

Postmenopausal women undergoing combination hormone therapy at increased risk of heart disease: WHI confirms

New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.

17 Feb 2010

Right-ventricular impairment increases risk of death in heart-failure patients

17 Feb 2010

ViewRay earns NorTech Innovation Award for advancements in cancer radiation therapy technology

ViewRay, Inc., a privately held medical device company, has earned a NorTech Innovation Award for its advancements in radiation therapy technology for the treatment of cancer. ViewRay was honored for its unique combination of medical imaging and radiotherapy, which is designed to improve the effectiveness of cancer treatments. Radiation therapy is used to treat nearly two-thirds of today's cancer patients.

17 Feb 2010

Even with new medical schools opening, shortages mar workforce

Nearly two dozen medical schools have recently opened or may open across America, "the most at any time since the 1960s and '70s," The New York Times reports. These new institutions "are seeking to address an imbalance in American medicine that has been growing for a quarter century. Many bright students were fleeing to offshore medical schools, or giving up hope entirely, when they could not get into domestic schools. Meanwhile, American hospitals were using foreign-trained and foreign-born physicians to fill medical residencies. During the 1980s and '90s only one new medical school was established."

17 Feb 2010

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

Amgen Inc. and Centocor Ortho Biotech Products, L.P., today announced that the U.S. Food and Drug Administration (FDA) has approved the Risk Evaluation and Mitigation Strategy (REMS) for erythropoiesis-stimulating agents (ESAs), which include Aranesp® (darbepoetin alfa), EPOGEN® (Epoetin alfa) and PROCRIT® (Epoetin alfa).

17 Feb 2010

Lungs News and Research

FDA's proposed label changes for LABA asthma medications: GSK reviews

Asthma: LABAs should not be used alone

Antigenics announces fourth-quarter and full-year 2009 financial results

Travellers are likely to become increasingly exposed to canecutter's disease: Study

Norwegian government task force suggests formation of single company to commercialise biomaterial assets

State-of-the-art review of stereological methods for lung morphometry

Pfizer Canada accepts entries for seventh round of competition for Pfizer CVRAP

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Sorin Group's newest generation C5 HLM system receives FDA clearance

Viral infection can suppress immune response to secondary bacterial infection

OTRC: Secondhand smoke exposure is a serious health hazard

Role of surgery and subsequent need for RT in treatment of stage I SCLC

Low RVEF increases risk of death in patients with systolic heart failure

Study: Earlier detection of lung cancer can reduce number of late stage lung cancer deaths

Research assesses the overall efficacy of palliative chest RT in patients with advanced NSCLC

Postmenopausal women undergoing combination hormone therapy at increased risk of heart disease: WHI confirms

Right-ventricular impairment increases risk of death in heart-failure patients

ViewRay earns NorTech Innovation Award for advancements in cancer radiation therapy technology

Even with new medical schools opening, shortages mar workforce

Amgen and Centocor Ortho Biotech Products: FDA approves REMS for Aranesp, EPOGEN and PROCRIT ESAs

The ultimate guide to lung research tools and protocols eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News